Therefore, estrogen suppression therapy and estrogen receptor antagonism therapy have become a new research direction; however, based on the results of most of the estrogen-specific therapies available, estrogen suppression therapy is ineffective in controlling LAM progression and even poses a greater risk. Here, ESR1 is linked to lymphangioleiomyomatosis.